Total Payments
$133,562
2024 Payments
$19.98
Companies
13
Transactions
65
Medicare Patients
1,894
Medicare Billing
$258,030
Payment Breakdown by Category
Research$124,006 (92.8%)
Travel$3,873 (2.9%)
Consulting$3,350 (2.5%)
Food & Beverage$2,259 (1.7%)
Education$73.39 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $124,006 | 16 | 92.8% |
| Travel and Lodging | $3,873 | 12 | 2.9% |
| Consulting Fee | $3,350 | 1 | 2.5% |
| Food and Beverage | $2,259 | 34 | 1.7% |
| Education | $73.39 | 2 | 0.1% |
Payments by Type
Research
$124,006
16 transactions
General
$9,555
49 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $117,799 | 13 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $6,713 | 21 | $0 (2021) |
| Chiesi USA, Inc. | $5,078 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $1,089 | 5 | $0 (2018) |
| Theravance Biopharma Inc. | $1,013 | 5 | $0 (2017) |
| Lupin Inc. | $1,000 | 1 | $0 (2018) |
| GlaxoSmithKline, LLC. | $334.40 | 9 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $267.70 | 4 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $129.72 | 1 | $0 (2019) |
| Jazz Pharmaceuticals Inc. | $84.28 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19.98 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($19.98) |
| 2021 | $204.06 | 6 | GlaxoSmithKline, LLC. ($162.51) |
| 2020 | $36.66 | 2 | Neurocrine Biosciences, Inc. ($19.29) |
| 2019 | $11,779 | 20 | AstraZeneca Pharmaceuticals LP ($6,429) |
| 2018 | $57,498 | 18 | Glenmark Pharmaceuticals Inc. ($54,861) |
| 2017 | $64,024 | 18 | Glenmark Pharmaceuticals Inc. ($62,937) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: RESPIRATORY | ||||||
| 07/07/2021 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $119.87 | General |
| Category: IMMUNOLOGY | ||||||
| 04/13/2021 | Bayer HealthCare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Cardio-pulmonary | ||||||
| 03/29/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $12.38 | General |
| Category: Respiratory | ||||||
| 03/09/2021 | GlaxoSmithKline, LLC. | ANORO ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: RESPIRATORY | ||||||
| 02/16/2021 | GlaxoSmithKline, LLC. | ANORO ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: RESPIRATORY | ||||||
| 02/16/2021 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: Respiratory | ||||||
| 05/15/2020 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: NEUROLOGY | ||||||
| 03/16/2020 | GlaxoSmithKline, LLC. | ANORO ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: RESPIRATORY | ||||||
| 12/06/2019 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: RESPIRATORY | ||||||
| 10/23/2019 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Travel and Lodging | In-kind items and services | $782.01 | General |
| Category: Respiratory | ||||||
| 10/23/2019 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $344.00 | General |
| Category: Respiratory | ||||||
| 10/23/2019 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Travel and Lodging | In-kind items and services | $324.05 | General |
| Category: Respiratory | ||||||
| 10/23/2019 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Travel and Lodging | In-kind items and services | $133.60 | General |
| Category: Respiratory | ||||||
| 06/19/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $116.36 | General |
| Category: Respiratory | ||||||
| 06/12/2019 | Chiesi USA, Inc. | — | — | Cash or cash equivalent | $5,078.12 | Research |
| Study: NONE | ||||||
| 05/21/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $127.58 | General |
| Category: RESPIRATORY | ||||||
| 04/07/2019 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,350.00 | General |
| 03/16/2019 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $871.74 | General |
| 03/16/2019 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $136.36 | General |
| 03/16/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $131.75 | General |
| 03/16/2019 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $72.86 | General |
| 03/16/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $49.59 | General |
| 03/16/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $38.30 | General |
| 03/16/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.82 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $62,937 | 11 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Glenmark Pharmaceuticals Inc. | $54,861 | 2 |
| NONE | Chiesi USA, Inc. | $5,078 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $1,000 | 1 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $129.72 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 234 | 342 | $62,532 | $21,356 |
| 2022 | 7 | 383 | 579 | $128,613 | $45,694 |
| 2021 | 9 | 524 | 956 | $156,320 | $79,017 |
| 2020 | 9 | 753 | 1,508 | $180,763 | $111,964 |
Total Patients
1,894
Total Services
3,385
Medicare Billing
$258,030
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 105 | 193 | $25,625 | $10,594 | 41.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 57 | $13,452 | $5,588 | 41.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 20 | 20 | $8,600 | $1,591 | 18.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $7,871 | $1,370 | 17.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $3,038 | $1,062 | 35.0% |
| 97750 | Test or measurement for functional capacity, each 15 minutes | Office | 2023 | 12 | 24 | $1,240 | $616.08 | 49.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 22 | 22 | $2,706 | $534.82 | 19.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 126 | 245 | $29,487 | $15,964 | 54.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 80 | 94 | $32,988 | $9,383 | 28.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 28 | $6,096 | $4,706 | 77.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 23 | 77 | $5,892 | $4,667 | 79.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $19,664 | $3,910 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 34 | 38 | $16,340 | $3,026 | 18.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 18 | 18 | $10,566 | $1,960 | 18.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $3,794 | $1,271 | 33.5% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 34 | 34 | $3,786 | $807.96 | 21.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 139 | 295 | $31,443 | $20,469 | 65.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 52 | 267 | $20,516 | $16,412 | 80.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 96 | 120 | $28,511 | $13,379 | 46.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 59 | 65 | $13,917 | $11,134 | 80.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 61 | $22,402 | $5,007 | 22.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 36 | 36 | $17,697 | $5,002 | 28.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 35 | $3,866 | $3,093 | 80.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 16 | 16 | $9,070 | $1,757 | 19.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 17 | 17 | $4,903 | $1,246 | 25.4% |
About Dr. James Pearle, M.D
Dr. James Pearle, M.D is a Pulmonary Disease healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982783940.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Pearle, M.D has received a total of $133,562 in payments from pharmaceutical and medical device companies, with $19.98 received in 2024. These payments were reported across 65 transactions from 13 companies. The most common payment nature is "" ($124,006).
As a Medicare-enrolled provider, Pearle has provided services to 1,894 Medicare beneficiaries, totaling 3,385 services with total Medicare billing of $258,030. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Internal Medicine
- Location Orange, CA
- Active Since 11/02/2006
- Last Updated 04/25/2023
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1982783940
Products in Payments
- BEVESPI AEROSPHERE (Drug) $1,593
- ADVAIR (Drug) $1,000
- FASENRA (Drug) $366.06
- NUCALA (Biological) $259.50
- OFEV (Drug) $147.56
- Fluticasone Propionate and Salmeterol (Drug) $129.72
- Xyrem (Drug) $84.28
- ANORO ELLIPTA (Drug) $60.01
- INGREZZA (Drug) $19.29
- CRESEMBA (Drug) $18.06
- Adempas (Drug) $16.88
- ANORO (Drug) $14.89
- STIOLTO (Drug) $13.89
- BREZTRI (Drug) $12.38
- FASENRA (Biological) $12.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Orange
Bassam Yaghmour, M.d, M.D
Pulmonary Disease — Payments: $317,412
Pulmonary Disease $317,412
Dr. Jasdeep Sidana, Md, MD
Pulmonary Disease — Payments: $40,012
Pulmonary Disease $40,012
Dr. Asad Javed, Medical Doctor, MEDICAL DOCTOR
Pulmonary Disease — Payments: $23,900
Pulmonary Disease $23,900
Jack Stewart, M.d, M.D
Pulmonary Disease — Payments: $20,129
Pulmonary Disease $20,129
Raymond Casciari, M.d, M.D
Pulmonary Disease — Payments: $17,121
Pulmonary Disease $17,121
Matthew Brenner, Md, MD
Pulmonary Disease — Payments: $16,169
Pulmonary Disease $16,169